Effect of L-carnitine on COVID-19
Phase 3
- Conditions
- Condition 1: Acute respiratory infection caused by coronavirus. Condition 2: Acute respiratory infection caused by coronavirus.COVID-19, virus not identifiedCOVID-19, virus identifiedU07.2U07.1
- Registration Number
- IRCT20151108024938N3
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
All patients COVID-19, admitted to intensive care unit
Age 18-65 years old
Satisfaction to participate in the study
Exclusion Criteria
Covid-19 with mold diarrhea
History of L-carnitine allergy
Use of anticonvulsant drugs
Hemodialysis
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Ventilator dependence. Timepoint: Before and 7 days after intervention. Method of measurement: Using ABG and the opinion of an anesthesiologist.;C-reactive protein (CRP). Timepoint: Before and 7 days after intervention. Method of measurement: Quantitative method, by ELISA method.
- Secondary Outcome Measures
Name Time Method Mortality within the intensive care unit. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Observe the occurrence.;The ratio of neutrophils to lymphocytes. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Using a complete blood test.;Blood levels of lactate dehydrogenase. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Enzymatic method.;The incidence of sepsis. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Based on the diagnosis of the treating physician and SIRS criteria.;The incidence of respiratory distress. Timepoint: Before intervention and 7 days after intervention. Method of measurement: Based on the diagnosis of the treating physician and SIRS criteria.